Literature DB >> 18523313

Hydrolysis of coagulation factors by circulating IgG is associated with a reduced risk for chronic allograft nephropathy in renal transplanted patients.

Bharath Wootla1, Antonino Nicoletti, Natacha Patey, Jordan D Dimitrov, Christophe Legendre, Olivier D Christophe, Alain Friboulet, Srinivas V Kaveri, Sébastien Lacroix-Desmazes, Olivier Thaunat.   

Abstract

Chronic allograft nephropathy (CAN), a major cause of late allograft failure, is characterized by a progressive decline in graft function correlated with tissue destruction. Uncontrolled activation of the coagulation cascade by the stressed endothelium of the graft is thought to play an important role in the pathophysiology of CAN. In this study, we demonstrate that circulating IgG from renal-transplanted patients are endowed with hydrolytic properties toward coagulation factors VIII and IX, but fail to hydrolyze factor VII and prothrombin. The hydrolytic activity of IgG was reliably quantified by the measure of the hydrolysis of a fluorescent synthetic substrate for serine proteases: proline-phenylalanine-arginine-methylcoumarinamide (PFR-MCA). A retrospective case-control study indicated that an elevated hydrolysis rate of PFR-MCA by circulating IgG correlated with the absence of CAN lesions on protocol graft biopsy performed 2 years posttransplantation. We propose that circulating hydrolytic IgG may counterbalance the procoagulation state conferred by the activated endothelium by disrupting the amplification loop of thrombin generation which is dependent on factors VIII and IX. Interestingly, low rates of PFR-MCA hydrolysis, measured 3 mo posttransplantation, were predictive of CAN at 2 years down the lane. These data suggest that PFR-MCA hydrolysis may be used as a prognosis marker for CAN in renal-transplanted patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18523313     DOI: 10.4049/jimmunol.180.12.8455

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Autoantibodies with enzymatic properties in human autoimmune diseases.

Authors:  Bharath Wootla; Sébastien Lacroix-Desmazes; Arthur E Warrington; Allan J Bieber; Srini V Kaveri; Moses Rodriguez
Journal:  J Autoimmun       Date:  2011-05-31       Impact factor: 7.094

Review 2.  Need for a paradigm shift in therapeutic approaches to CNS injury.

Authors:  Bharath Wootla; Aleksandar Denic; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Rev Neurother       Date:  2012-04       Impact factor: 4.618

3.  Constant domain-regulated antibody catalysis.

Authors:  Gopal Sapparapu; Stephanie Planque; Yukie Mitsuda; Gary McLean; Yasuhiro Nishiyama; Sudhir Paul
Journal:  J Biol Chem       Date:  2012-09-04       Impact factor: 5.157

4.  In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy.

Authors:  Qiao Li; Seagal Teitz-Tennenbaum; Elizabeth J Donald; Mu Li; Alfred E Chang
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

Review 5.  Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies.

Authors:  Géraldine Lavigne-Lissalde; Chantal Rothschild; Claire Pouplard; Priscilla Lapalud; Yves Gruel; Jean-François Schved; Claude Granier
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

6.  Generation of Catalytic Antibodies Is an Intrinsic Property of an Individual's Immune System: A Study on a Large Cohort of Renal Transplant Patients.

Authors:  Ankit Mahendra; Ivan Peyron; Olivier Thaunat; Cécile Dollinger; Laurent Gilardin; Meenu Sharma; Bharath Wootla; Desirazu N Rao; Séverine Padiolleau-Lefevre; Didier Boquet; Abhijit More; Navin Varadarajan; Srini V Kaveri; Christophe Legendre; Sébastien Lacroix-Desmazes
Journal:  J Immunol       Date:  2016-04-11       Impact factor: 5.422

Review 7.  Varied immune response to FVIII: presence of proteolytic antibodies directed to factor VIII in different human pathologies.

Authors:  Bharath Wootla; Desirazu Narasimha Rao; Narasimha Rao Desirazu; Alain Friboulet; Taizo Uda; Sébastien Lacroix-Desmazes; Srini V Kaveri
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

Review 8.  B-cell-mediated strategies to fight chronic allograft rejection.

Authors:  Ali Dalloul
Journal:  Front Immunol       Date:  2013-12-17       Impact factor: 7.561

9.  IVIg treatment reduces catalytic antibody titers of renal transplanted patients.

Authors:  Ankit Mahendra; Ivan Peyron; Cécile Dollinger; Laurent Gilardin; Meenu Sharma; Bharath Wootla; Séverine Padiolleau-Lefevre; Alain Friboulet; Didier Boquet; Christophe Legendre; Srinivas V Kaveri; Olivier Thaunat; Sébastien Lacroix-Desmazes
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

10.  Immunoglobulins with Non-Canonical Functions in Inflammatory and Autoimmune Disease States.

Authors:  Evgeny A Ermakov; Georgy A Nevinsky; Valentina N Buneva
Journal:  Int J Mol Sci       Date:  2020-07-29       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.